As of 11 May, the Likelihood of Approval (LoA) for United Therapeutics’ (NASDAQ:UTHR) Unituxin (dinutuximab) for osteosarcoma dropped 12 points, according to GlobalData’s LoA data. This news is the result of a Phase II trial, sponsored by the National Cancer Institute (NCI), that showed Unituxin was ineffective in patients with recurrent osteosarcoma, in a 7 May update to ClinicalTrials.gov.

Though 41 patients enrolled in the Phase II, 32 did not complete the study, including 28 patients who dropped out due to a lack of efficacy, according to ClinicalTrials.gov. In addition, 30.77% of patients experienced serious adverse events, including eye disorders and vomiting. Unituxin previously received FDA approval for treating neuroblastoma in March 2015 and had sales of $123m in 2020 for that indication, according to GlobalData.

While the LoA prior to this news was 15%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has dropped the LoA to 3%. Unituxin is an intravenously administered monoclonal antibody.

United Therapeutics has a market cap of $8.68bn.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.